LB Pharmaceuticals Inc (LBRX) Stock Price & Analysis

LB Pharmaceuticals Inc (LBRX) closed at USD 39.83 on Wednesday, October 28, 2026, up 0.48% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 39.64; the Oct 28, 2026 session ranged USD 38.49–40.38 on volume of 201,736 shares. Market capitalization is $1.28B, with a 52-week range of USD 14.32–50.16 (NGM). Source: Nexqual, retrieved October 29, 2026 at 06:00 UTC.

Also available as compact Markdown for AI agents: nexqual.com/LBRX.md

Key facts (LBRX)

• Analysts: Buy (mean 1.91 on a 1–5 scale) (11 analysts), mean target USD 58 (range 35–80).
• Total return with dividends: 1Y +154.5% vs S&P 500 +13.6%; 5Y +137.1% vs S&P 500 +79.8%.
• Next earnings: 2026-11-12, EPS estimate USD -1.52, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LBRX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (LBRX)

P/B 3.9x · FCF yield -6.45% · Earnings yield -6.67%

Analysts (LBRX)

Consensus Buy (mean 1.91 on a 1–5 scale), 11 analysts; mean target USD 58 (low 35, high 80).

Rating changes, last 120 days:

Total return (dividends reinvested) (LBRX)

LBRX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

LBRX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

LBRX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 26, 2026.

LBRX company outlook (results filed Aug 11, 2026)

• “We are looking forward to our first pivotal trial readout and recently announced that, based on enrollment in our pivotal NOVA-2 trial in schizophrenia being more rapid than expected, we now project topline data readout in the first half of 2027, ahead of our prior guidance, and plan to schedule a pre-NDA meeting with the FDA soon thereafter in the second half of 2027.”
• “LB-102 in Schizophrenia • Based on enrollment projections in the pivotal Phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 in patients with acute schizophrenia, topline data is expected in the first half of 2027.”
• “Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and marketable securities will support its planned operations beyond the second quarter of 2029.”

Quoted word-for-word from the SEC 8-K results press release.

LBRX analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 06:00 UTC)

Technical Analysis (LBRX)

Nexqual's technical model rates LBRX "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 06:00 UTC.

Analyst Ratings (LBRX)

Wall Street analysts rate LBRX "Buy" based on 11 analysts, with a mean price target of USD 58 (range USD 35–80), per Nexqual as of October 29, 2026 at 06:00 UTC.

Earnings (LBRX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 06:00 UTC.

Financials & Fundamentals (LBRX)

Source: Nexqual, October 29, 2026 at 06:00 UTC.

Financial Health Score (LBRX)

Nexqual rates LB Pharmaceuticals Inc's overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 06:00 UTC.

Ownership (LBRX)

Source: Nexqual, October 29, 2026 at 06:00 UTC.

Leadership (LBRX)

LB Pharmaceuticals Inc is led by Heather D. Turner Esq., CEO & Director, per Nexqual as of October 29, 2026 at 06:00 UTC.

Major Backers & Investors (LBRX)

Notable institutional backers of LB Pharmaceuticals Inc include Deep Track Capital, Lp, RA Capital Management, L.P., Trails Edge Capital Partners, LP, according to Nexqual as of October 29, 2026 at 06:00 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 06:00 UTC.

From LB Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.
• The adequacy of our Phase 2 trial to support registration will be a matter of review by the FDA at the time of NDA submission and will depend on the totality of the data included in our submission, including the results of our planned Phase 3 trial.
• Amisulpride is a dopamine receptor antagonist originally developed in France in the 1980s and is approved in more than 50 countries worldwide (not including the United States) for the treatment of schizophrenia and, in certain countries outside of the United States, for the treatment of dysthymia, a form of depression, and predominantly negative symptoms of schizophrenia.
• For example, we have developed a synopsis for a Phase 2 trial in patients with predominantly negative symptoms of schizophrenia and expect to seek regulatory guidance on the design of this trial in 2026 to establish a clinical registration path in this setting.

Legal & Regulatory Risks (Item 1A, quoted)

• Our relationships with healthcare providers, including physicians, and third-party payors may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to significant penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.
• We intend to seek approval to market our product candidate in the United States and we may also seek to do so in selected foreign jurisdictions, including the European Union.
• The FDA or comparable foreign regulatory authorities may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.
• The policies of the FDA and comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidate.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:00 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt